BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, Shaheen M, Vinik A; ELECT Study Group. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. Oncologist 2018;23:16-24. [PMID: 29038234 DOI: 10.1634/theoncologist.2017-0284] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Duck L, Demolin G, D'Hondt L, Dopchie C, Hendrickx K, Lannoye B, Bastin F, Lossignol D, Hamdan O, Lybaert W, Vandenhaute V, Regnault B, De Ruyter V, Geboes K. Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study. Clin Ther 2021;43:2136-2145.e2. [PMID: 34844770 DOI: 10.1016/j.clinthera.2021.10.014] [Reference Citation Analysis]
2 Blot K, Duchateau L, Lescrauwaet B, Liyanage N, Ray D, Mirakhur B, Vinik AI. A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial. Patient Relat Outcome Meas 2019;10:335-43. [PMID: 31754316 DOI: 10.2147/PROM.S219982] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 La Salvia A, Portigliatti Pomeri A, Persano I, Trevisi E, Parlagreco E, Colombi N, Brizzi MP, Picci RL, Oliva F. Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review. Compr Psychiatry 2021;109:152244. [PMID: 34120056 DOI: 10.1016/j.comppsych.2021.152244] [Reference Citation Analysis]
4 Hayes AR, Chan DLH, Chan BA, Pavlakis N. The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials. J Neuroendocrinol 2021;:e13015. [PMID: 34397130 DOI: 10.1111/jne.13015] [Reference Citation Analysis]
5 Rustgi SD, Oh A, Yang JY, Kang D, Wolin E, Kong CY, Hur C, Kim MK. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer 2021;21:597. [PMID: 34030646 DOI: 10.1186/s12885-021-08306-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
7 Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, Lowenthal SP, Vinik AI. Biochemical Responses in Symptomatic and Asymptomatic Patients with Neuroendocrine Tumors: Pooled Analysis of Two Phase 3 Trials. Endocrine Practice 2018;24:948-62. [DOI: 10.4158/ep-2018-0296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
8 Pusceddu S, Rossi RE, Torchio M, Prinzi N, Niger M, Coppa J, Giacomelli L, Sacco R, Facciorusso A, Corti F, Raimondi A, Prisciandaro M, Colombo E, Beninato T, Del Vecchio M, Milione M, Di Bartolomeo M, de Braud F. Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. J Clin Med 2020;9:E2468. [PMID: 32752158 DOI: 10.3390/jcm9082468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Walter MA, Nesti C, Spanjol M, Kollár A, Bütikofer L, Gloy VL, Dumont RA, Seiler CA, Christ ER, Radojewski P, Briel M, Kaderli RM. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. Cochrane Database Syst Rev 2021;11:CD013700. [PMID: 34822169 DOI: 10.1002/14651858.CD013700.pub2] [Reference Citation Analysis]
10 Marinova M, Mücke M, Fischer F, Essler M, Cuhls H, Radbruch L, Ghaei S, Conrad R, Ahmadzadehfar H. Quality of life in patients with midgut NET following peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2019;46:2252-9. [PMID: 31338547 DOI: 10.1007/s00259-019-04431-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]